WO2014140374A3 - Monovalent cd27 antibodies - Google Patents

Monovalent cd27 antibodies Download PDF

Info

Publication number
WO2014140374A3
WO2014140374A3 PCT/EP2014/055331 EP2014055331W WO2014140374A3 WO 2014140374 A3 WO2014140374 A3 WO 2014140374A3 EP 2014055331 W EP2014055331 W EP 2014055331W WO 2014140374 A3 WO2014140374 A3 WO 2014140374A3
Authority
WO
WIPO (PCT)
Prior art keywords
monovalent antibody
monovalent
conjugate
fusion protein
relates
Prior art date
Application number
PCT/EP2014/055331
Other languages
French (fr)
Other versions
WO2014140374A2 (en
Inventor
Albrecht Gruhler
Peder Lisby NØRBY
Louise Hjerrild ZEUTHEN
Leif Christensen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of WO2014140374A2 publication Critical patent/WO2014140374A2/en
Publication of WO2014140374A3 publication Critical patent/WO2014140374A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a monovalent antibody, such as a Fab fragment, which is capable of specifically binding CD27 and reducing CD27 induced signalling. The present invention also relates to a fusion protein or conjugate comprising the monovalent antibody of the invention and a half-life extending moiety. The monovalent antibody, fusion protein or conjugate of the invention may be suitable for use as a medicament, such as in the treatment of autoimmune diseases in which suppression of CD27 signaling is desirable.
PCT/EP2014/055331 2013-03-15 2014-03-17 Monovalent cd27 antibodies WO2014140374A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361788554P 2013-03-15 2013-03-15
EP13159432 2013-03-15
US61/788,554 2013-03-15
EP13159432.7 2013-03-15

Publications (2)

Publication Number Publication Date
WO2014140374A2 WO2014140374A2 (en) 2014-09-18
WO2014140374A3 true WO2014140374A3 (en) 2014-12-04

Family

ID=47877931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/055331 WO2014140374A2 (en) 2013-03-15 2014-03-17 Monovalent cd27 antibodies

Country Status (1)

Country Link
WO (1) WO2014140374A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10174119B2 (en) 2016-03-31 2019-01-08 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CN109475603B (en) 2016-06-20 2023-06-13 科马布有限公司 anti-PD-L1 antibodies
MX2019013514A (en) 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology.
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
JP2022531185A (en) 2019-04-30 2022-07-06 クリスパー セラピューティクス アクチェンゲゼルシャフト Allogeneic cell therapy for B cell malignancies using CD19 targeting genetically modified T cells
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2023532339A (en) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Viruses engineered to promote sanotransmission and their use in treating cancer
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130434A2 (en) * 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
WO2012004367A1 (en) * 2010-07-09 2012-01-12 N.V. Organon Agonistic antibody to cd27
WO2013138586A1 (en) * 2012-03-15 2013-09-19 Janssen Biotech, Inc. Human anti-cd27 antibodies, methods and uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130434A2 (en) * 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
WO2012004367A1 (en) * 2010-07-09 2012-01-12 N.V. Organon Agonistic antibody to cd27
WO2013138586A1 (en) * 2012-03-15 2013-09-19 Janssen Biotech, Inc. Human anti-cd27 antibodies, methods and uses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AGEMATSU K ET AL: "B CELL SUBPOPULATIONS SEPARATED BY CD27 AND CRUCIAL COLLABORATION OF CD27+ B CELLS AND HELPER T CELLS IN IMMUNOGLOBULIN PRODUCTION", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 27, no. 8, 1 January 1997 (1997-01-01), WILEY - V C H VERLAG GMBH & CO. KGAA, DE, pages 2073 - 2079, XP001031448, ISSN: 0014-2980, DOI: 10.1002/EJI.1830270835 *
GREENALL SAMEER A ET AL: "Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.", PLOS ONE, vol. 7, no. 4, E34658, April 2012 (2012-04-01), pages 1 - 10, XP002697775, ISSN: 1932-6203 *
JEVSEVAR SIMONA ET AL: "PEGylation of antibody fragments for half-life extension", METHODS IN MOLECULAR BIOLOGY, vol. 901, 1 January 2012 (2012-01-01), (CLIFTON, N.J.) UNITED STATES, pages 233 - 246, XP009169915, ISSN: 1940-6029 *
KOBATA T ET AL: "CD27-CD70 interactions regulate B-cell activation by T cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 92, no. 24, 21 November 1995 (1995-11-21), NATIONAL ACADEMY OF SCIENCES, US, pages 11249 - 11253, XP002582843, ISSN: 0027-8424, DOI: 10.1073/PNAS.92.24.11249 *
MAGE R G ET AL: "B cell and antibody repertoire development in rabbits: The requirement of gut-associated lymphoid tissues", DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, PERGAMON PRESS, US, vol. 30, no. 1-2, 1 January 2006 (2006-01-01), pages 137 - 153, XP027942078, ISSN: 0145-305X, [retrieved on 20060101] *
MATTHIAS MATTER ET AL: "Elimination of chronic viral infection by blocking CD27 signaling", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 203, no. 9, 21 August 2006 (2006-08-21), ROCKEFELLER UNIVERSITY PRESS, US, pages 2145 - 2155, XP007906013, ISSN: 0022-1007, DOI: 10.1084/JEM.20060651 *
NAKAJIMA A ET AL: "Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis", JOURNAL OF NEUROIMMUNOLOGY, vol. 109, no. 2, 22 September 2000 (2000-09-22), ELSEVIER SCIENCE PUBLISHERS BV, pages 188 - 196, XP002423716, ISSN: 0165-5728, DOI: 10.1016/S0165-5728(00)00324-6 *

Also Published As

Publication number Publication date
WO2014140374A2 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
WO2014140374A3 (en) Monovalent cd27 antibodies
PH12018501882A1 (en) Binding proteins and methods of use thereof
MX2019011952A (en) Anti-garp protein and uses thereof.
MX2022002504A (en) Antibodies to cd40.
MY193249A (en) Anti-human cd19 antibodies with high affinity
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
WO2011113019A3 (en) Ctla4 proteins and their uses
WO2013072813A3 (en) Cytotoxic peptides and antibody drug conjugates thereof
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
EA201291067A1 (en) HUMANIZED ANTIGENSORATING PROTEINS FOR MYOSTATIN
WO2014144791A3 (en) Therapeutic peptides
NZ630881A (en) Use of semaphorin-4d binding molecules for treatment of atherosclerosis
WO2012017324A3 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
PH12014502406B1 (en) Anti-il-23p19 antibodies
WO2014163714A3 (en) Antibody drug conjugates
WO2014150877A3 (en) Anti-tau antibodies and methods of use
MX2015011199A (en) Csf1 therapeutics.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
PH12016500123A1 (en) Therapeutic fusion protein
WO2012006341A3 (en) Anti-ron antibodies
WO2013149111A3 (en) Anti-tlr4 antibodies and uses thereof
CA2866232A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
UA118674C2 (en) Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
WO2014144621A3 (en) Modified fc fusion proteins
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14710326

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14710326

Country of ref document: EP

Kind code of ref document: A2